Microbiome-Focused Seres Therapeutics Inc. Announces Proposed Common Stock Offering

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome,  announced on 6/12/19 that it is commencing an underwritten registered public offering of $60.0 million of shares of its common stock.